

# Mattia Barbot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2912959/publications.pdf>

Version: 2024-02-01

60  
papers

1,539  
citations

304602

22  
h-index

345118

36  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1481  
citing authors

#	ARTICLE	IF	CITATIONS
1	The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice. <i>European Journal of Endocrinology</i> , 2014, 171, 1-7.	1.9	161
2	Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?. <i>Pituitary</i> , 2014, 17, 109-117.	1.6	86
3	Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2013, 169, 31-36.	1.9	69
4	An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. <i>Clinical Endocrinology</i> , 2015, 82, 808-815.	1.2	62
5	Diagnosis and complications of Cushing's disease: gender-related differences. <i>Clinical Endocrinology</i> , 2014, 80, 403-410.	1.2	60
6	Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101380.	2.2	60
7	Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3856-3861.	1.8	56
8	Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. <i>Pituitary</i> , 2016, 19, 488-495.	1.6	52
9	The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 321.	1.5	50
10	Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?. <i>Pituitary</i> , 2015, 18, 487-493.	1.6	45
11	Metyrapone treatment in Cushing's syndrome: a real-life study. <i>Endocrine</i> , 2018, 62, 701-711.	1.1	44
12	Predicting late recurrence in surgically treated patients with Cushing's disease. <i>Clinical Endocrinology</i> , 2013, 79, 394-401.	1.2	42
13	Diabetes Mellitus Secondary to Cushing's Disease. <i>Frontiers in Endocrinology</i> , 2018, 9, 284.	1.5	42
14	Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. <i>Anti-Cancer Drugs</i> , 2020, 31, 199-204.	0.7	40
15	Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2016, 175, 101-106.	1.9	36
16	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 703-714.	2.6	36
17	Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1105-1113.	1.8	36
18	A venous thromboembolism risk assessment model for patients with Cushing's syndrome. <i>Endocrine</i> , 2016, 52, 322-332.	1.1	35

#	ARTICLE	IF	CITATIONS
19	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 813-824.	5.5	34
20	Early recognition of aggressive pituitary adenomas: a single-centre experience. <i>Acta Neurochirurgica</i> , 2018, 160, 49-55.	0.9	32
21	Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. <i>Endocrine</i> , 2018, 59, 510-519.	1.1	32
22	Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. <i>Pituitary</i> , 2020, 23, 359-366.	1.6	25
23	Improved salivary cortisol rhythm with dual-release hydrocortisone. <i>Endocrine Connections</i> , 2018, 7, 965-974.	0.8	24
24	Radiomics: a new tool to differentiate adrenocortical adenoma from carcinoma. <i>BJS Open</i> , 2021, 5, .	0.7	24
25	Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?. <i>Pituitary</i> , 2014, 17, 68-75.	1.6	22
26	Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3938-e3949.	1.8	22
27	Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report. <i>Frontiers in Endocrinology</i> , 2020, 11, 554.	1.5	21
28	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH-dependent Cushing's syndrome. <i>Clinical Endocrinology</i> , 2017, 87, 500-507.	1.2	19
29	The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 165-183.	2.6	17
30	Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients. <i>Endocrine</i> , 2019, 66, 360-369.	1.1	16
31	Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9554.	1.8	15
32	Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism. <i>Annals of Laboratory Medicine</i> , 2021, 41, 521-531.	1.2	15
33	Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 629-637.	1.8	15
34	Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease. <i>Endocrine</i> , 2018, 62, 207-214.	1.1	14
35	Frequently asked questions and answers (if any) in patients with adrenal incidentaloma. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2749-2763.	1.8	14
36	Age and the metabolic syndrome affect salivary cortisol rhythm: data from a community sample. <i>Hormones</i> , 2015, 14, 392-8.	0.9	13

#	ARTICLE	IF	CITATIONS
37	Preoperative treatment with metyrapone in patients with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. <i>Endocrine Connections</i> , 2018, 7, 1227-1235.	0.8	13
38	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study. <i>Endocrine</i> , 2015, 50, 154-161.	1.1	12
39	Perioperative multidisciplinary management of endoscopic transsphenoidal surgery for sellar lesions: practical suggestions from the Padova model. <i>Neurosurgical Review</i> , 2020, 43, 1109-1116.	1.2	12
40	Pituitary-adrenal axis and peripheral cortisol metabolism in obese patients. <i>Endocrine</i> , 2020, 69, 386-392.	1.1	12
41	Clinical presentation and management of acromegaly in elderly patients. <i>Hormones</i> , 2021, 20, 143-150.	0.9	11
42	Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. <i>Pituitary</i> , 2021, 24, 914-921.	1.6	10
43	Therapeutic strategies for Cushing's syndrome: an update. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 45-56.	0.5	9
44	Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study. <i>Clinical Endocrinology</i> , 2018, 88, 201-208.	1.2	9
45	The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome. <i>Endocrine Connections</i> , 2020, 9, 337-345.	0.8	8
46	New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. <i>Microvascular Research</i> , 2020, 128, 103940.	1.1	7
47	Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. <i>Pituitary</i> , 2020, 23, 534-542.	1.6	7
48	Allelic Variants of ARMC5 in Patients With Adrenal Incidentalomas and in Patients With Cushing's Syndrome Associated With Bilateral Adrenal Nodules. <i>Frontiers in Endocrinology</i> , 2020, 11, 36.	1.5	7
49	Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study. <i>Hormone and Metabolic Research</i> , 2016, 48, 514-519.	0.7	6
50	Body Composition is Different After Surgical or Pharmacological Remission of Cushing's Syndrome: A Prospective DXA Study. <i>Hormone and Metabolic Research</i> , 2017, 49, 660-666.	0.7	6
51	Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. <i>Pituitary</i> , 2018, 21, 50-55.	1.6	4
52	Consideration on TMPRSS2 and the risk of COVID-19 infection in Cushing's syndrome. <i>Endocrine</i> , 2020, 69, 235-236.	1.1	4
53	Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency. <i>Endocrine Connections</i> , 2021, 10, 1189-1199.	0.8	4
54	Pitfalls in urinary sodium excretion. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1635-1636.	1.0	3

#	ARTICLE	IF	CITATIONS
55	The haemostatic system in acromegaly: a single-centre caseâ€“control study. Journal of Endocrinological Investigation, 2020, 43, 1009-1018.	1.8	2
56	Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2023, 23, 188-195.	0.6	2
57	The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas. International Journal of Molecular Sciences, 2022, 23, 6469.	1.8	2
58	Preoperative treatment with metyrapone in patient with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. Endocrine Abstracts, 0, , .	0.0	1
59	Hypertension in Cushingâ€™s Syndrome. Updates in Hypertension and Cardiovascular Protection, 2020, , 127-139.	0.1	1
60	Incretin Response to Mixed Meal Challenge in Active Cushingâ€™s Disease and after Pasireotide Therapy. International Journal of Molecular Sciences, 2022, 23, 5217.	1.8	1